Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets

• Status: COMPLETED
• Trial end date: 2024-05-27

Summary

Randomized, two-way, two-period, single oral dose, open-label, crossover, bioequivalence study to compare Bosentan 32 mg Dispersible Tablets versus Tracleer® 32 mg Tablets for Oral Suspension (Tracleer® 32 mg Dispersible Tablet) (Bosentan), in healthy subjects under fasting condition.

• Phase: PHASE1

Details

• Lead Sponsor: Humanis Saglık Anonim Sirketi
• Treatments: Bosentan; Suspensions